CliffBio
biologic

Skyrizi

risankizumab-rzaa

Loss of exclusivitySeptember 2034projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSkyrizi
Active ingredientrisankizumab-rzaa
Strength180MG/1.2ML (150MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2022
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Skyrizi patent cliff — loss of exclusivity September 2034 | CliffBio